Conference Coverage

Emphasis on weight loss in new type 2 diabetes guidance


 

AT EASD 2022

Individualization featured throughout

The report’s sections cover principles of care, including the importance of diabetes self-management education and support and avoidance of therapeutic inertia. Detailed guidance addresses therapeutic options including lifestyle, weight management, and pharmacotherapy for treating type 2 diabetes.

Another entire section is devoted to personalizing treatment approaches based on individual characteristics, including new evidence from cardiorenal outcomes studies for SGLT2 inhibitors and GLP-1 agonists that have come out since the last consensus report.

The document advises: “Consider initial combination therapy with glucose-lowering agents, especially in those with high [hemoglobin] A1c at diagnosis (that is, > 70 mmol/mol [> 8.5%]), in younger people with type 2 diabetes (regardless of A1c), and in those in whom a stepwise approach would delay access to agents that provide cardiorenal protection beyond their glucose-lowering effects.”

Designed to be used and user-friendly

Under the “Putting it all together: strategies for implementation” section, several lists of “practical tips for clinicians” are provided for many of the topics covered.

A series of colorful infographics are included as well, addressing the “decision cycle for person-centered glycemic management in type 2 diabetes,” including a chart summarizing characteristics of available glucose-lowering medications, including cardiorenal protection.

Also mentioned is the importance of 24-hour physical behaviors (including sleep, sitting, and sweating) and the impact on cardiometabolic health, use of a “holistic person-centered approach” to type 2 diabetes management, and an algorithm on insulin use.

Dr. Buse has financial ties to numerous drug and device companies. Dr. Green is a consultant for AstraZeneca, Pfizer, Boehringer Ingelheim/Lilly, Bayer, Sanofi, Anji, Vertex/ICON, and Valo. Dr. Aroda has served as a consultant for Applied Therapeutics, Duke, Fractyl, Novo Nordisk, Pfizer, and Sanofi.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Could exercise improve bone health in youth with type 1 diabetes?
MDedge Family Medicine
‘Amazing’ data for cheap beta-blocker gel for diabetic foot ulcers
MDedge Family Medicine
Early bird gets the worm, night owl gets the diabetes
MDedge Family Medicine
Night owls may have greater risks of T2D and CVD
MDedge Family Medicine
Mothers’ diabetes linked to ADHD in their children
MDedge Family Medicine
Could cold exposure, especially shivering, combat type 2 diabetes?
MDedge Family Medicine
Type 1 diabetes complication risk rises with A1c, duration
MDedge Family Medicine
Early age at hysterectomy ups type 2 diabetes risk
MDedge Family Medicine
Unsure on the best T2D drug choice? Let patients decide
MDedge Family Medicine
Presence of community health workers linked with better results in patients with T2D
MDedge Family Medicine